12:17 ET -- Hims & Hers Health is showing off an impressive growth trajectory for revenue that's being undercut by profitability concerns, Truist analysts say in a research note. The telehealth company raised its full-year revenue outlook on the back of its international expansion and shift toward branded weight-loss drugs, the analysts say. Most of the raise came from the inclusion of Hims' recent acquisition of Eucalyptus, they say. But investors are still debating whether the company can hit profit targets for the second half of the year, they say. Gross margins dropped in 2Q because selling third-party branded GLP-1s yields lower margins than the company's traditional compounded treatments, the analysts say, reiterating their hold rating on the stock. Shares slip 2.5% to $30.97.
Comments